key: cord-0865351-98fwm2sk
authors: Macip, Guillem; Garcia‐Segura, Pol; Mestres‐Truyol, Júlia; Saldivar‐Espinoza, Bryan; Ojeda‐Montes, María José; Gimeno, Aleix; Cereto‐Massagué, Adrià; Garcia‐Vallvé, Santiago; Pujadas, Gerard
title: Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition
date: 2021-10-26
journal: Med Res Rev
DOI: 10.1002/med.21862
sha: 3a0f7af94717bfd73958529e234024dca6b0819f
doc_id: 865351
cord_uid: 98fwm2sk

This review makes a critical evaluation of 61 peer‐reviewed manuscripts that use a docking step in a virtual screening (VS) protocol to predict SARS‐CoV‐2 M‐pro (M‐pro) inhibitors in approved or investigational drugs. Various manuscripts predict different compounds, even when they use a similar initial dataset and methodology, and most of them do not validate their methodology or results. In addition, a set of known 150 SARS‐CoV‐2 M‐pro inhibitors extracted from the literature and a second set of 81 M‐pro inhibitors and 113 inactive compounds obtained from the COVID Moonshot project were used to evaluate the reliability of using docking scores as feasible predictors of the potency of a SARS‐CoV‐2 M‐pro inhibitor. Using two SARS‐CoV‐2 M‐pro structures and five protein‐ligand docking programs, we proved that the correlation between the pIC(50) and docking scores is not good. Neither was any correlation found between the pIC(50) and the ∆G calculated with an MM‐GBSA method. When a group of experimentally known inactive compounds was added, neither the docking scores or the ∆G were able to distinguish between compounds with or without M‐pro experimental inhibitory activity. Performances improved when covalent and noncovalent inhibitors were treated separately, but were not good enough to fully support using a docking score as a cutoff value for selecting new putative M‐pro inhibitors or predicting the relative bioactivity of a compound by comparison with a reference compound. The two sets of known SARS‐CoV‐2 M‐pro inhibitors presented here could be used for validating future VS protocols which aim to predict M‐pro inhibitors.

humans have been identified. 9 But our main concern here lies within the Betacoronavirus genus which contains the severe acute respiratory syndrome (SARS) viruses. SARS-like viruses emerged as human infectious diseases in 2002, and since then have caused several epidemics and outbreaks. Before COVID-19, outbreaks of SARS in 2003 10 and Middle East Respiratory Syndrome (MERS) in 2012 11 

Betacoronaviruses. The causative agent of COVID-19 is SARS-CoV-2. 12 This virus has the capacity to affect multiple organs as well as the central nervous system and sometimes causes respiratory problems which might end up having fatal consequences. The SARS-CoV-2 genome consists of around 30,000 nucleotides and contains 12 functional open reading frames (ORFs): from 5′ to 3′, ORF1a, ORF1b, S, ORF3a, E, M, ORF6, ORF7a, ORF7b, ORF8, N, and ORF10. 13, 14 Two-thirds of the SARS-CoV-2 genome, located at the 5′ genomic region, codify the ORF1a and ORF1b genes, which encode the polyproteins pp1a and pp1ab. Polyprotein pp1ab contains the pp1a protein and its synthesis requires a −1 ribosomal frameshift. 15 Both polyproteins are further cleaved by the main protease (M-pro, also known as 3CLpro) and papain-like (PLpro) protease to produce 16 proteins that include both proteases, an RNA-dependent RNA polymerase, a helicase, two nucleases and a methyltransferase, among other proteins. 15 Due to the lack of target-specific drugs for treating COVID-19, several strategies are being investigated.

Among these strategies, several clinical trials are being developed to: (i) inhibit the RNA-dependent RNA polymerase, 16, 17 (ii) inhibit the viral M-pro or PLpro proteases, [18] [19] [20] [21] (iii) block the fusion with the host cells, 22-24 (iv) enhance the innate immune system, 25 (v) attenuate the inflammatory response, 26 (vi) control the symptoms, 27 and (vii) create pathogen-specific artificial antigen-presenting cells. 28 Given its importance in the replication of SARS-CoV-2, M-pro has become a key target for the development of antiviral drugs. 29 M-pro proteins from SARS-CoV-2 and SARS-CoV show a high sequence (i.e., >96%) and structural similarity (i.e., an root mean-squared deviation

[RMSD] of 0.44 Å between the Cα of both structures). SARS-CoV-2 M-pro has a length of 306 amino acids that form three different domains (domains I, II, and III). 30 The substrate-binding site is located at a cleft between domain I (residues 8-101) and domain II (residues 102-184), which share a common fold consisting of antiparallel ß-barrel structures ( Figure 1 ). Domain III (residues 201-303) consists of an antiparallel globular cluster of five alpha-helices F I G U R E 1 SARS-CoV-2 M-Pro homodimer (PDBid 6LU7). Panel (B) shows an overview of the main structural features of M-Pro and panel (A) displays in detail one of its binding pockets where the co-crystallized ligand N3, in grey, fits. Each of the two protomers is a different tone of blue. In both panels, the residues that form the binding pocket (according to Gimeno et al. 29 ) are also highlighted in ball and stick format and the residues of the catalytic dyad (His41 and Cys145) are colored orange and labeled. This figure has been generated using the Flare software. [32] [33] [34] and is involved in M-pro dimerization, which is essential for M-pro activity. 30 Unlike the conventional Ser(Cys)-His-Asp(Glu) triad found in other chymotrypsin-like enzymes, SARS-CoV-2 M-pro has a catalytic dyad formed by His41 and Cys145 (Figure 1 ) that catalyzes the hydrolysis of the peptide bond at highly specific sites of a polypeptide chain through a common nucleophilic-type reaction. It was suggested that a water molecule might complete the catalytic triad by mediating crucial interactions between His41 and other important conserved residues, such as His164 and Asp187. 31 While noncovalent small inhibitors have the ability to interact with different residues that lie within the binding pocket of SARS-CoV-2 M-pro, covalent inhibitors are found to mainly interact with the catalytic cysteine residue after an initial noncovalent mechanistic step that ensures the warhead is correctly oriented. 21 Thus, it is of great importance to consider covalent and noncovalent inhibitors as different, because their binding mode and mode of action are quite distinct. Most of the characterized SARS-CoV-2 M-pro inhibitors were originally designed for other pathogens, such as SARS-CoV, HIV and Hepatitis C viruses, which shows the importance of drug repurposing strategies.

Drug repurposing, also known as drug repositioning, is a well-known strategy in drug development, that is used to identify new medical uses for already approved or investigational drugs. This has enormous advantages compared to traditional drug development from scratch. Briefly, drug repurposing shortens time-consuming steps in drug development, as safety assessment and testing are usually completed, while it is also known to substantially diminish the investment needed. This, together with the decreased risk of failure, makes drug repurposing an interesting approach when time presses, such as in a global pandemic like COVID-19. 35 Given the high throughput of computational approaches, they are one of the mainstays of drug repurposing. Specifically, the most popular structure-based in silico approach, protein-ligand molecular docking, has been extensively used not only in drug discovery but also in drug repurposing. 36, 37 Molecular docking is a receptor-based VS method, that can be used to assess the possible binding poses of the ligands (e.g., a library of approved drugs) to a target (e.g., SARS-CoV-2 M-pro). Thus, molecular docking makes it possible to interrogate thousands of drugs against the protein target at a relatively low computational cost, so it is a popular tool in computational and structural biology.

Several articles have reviewed the SARS-CoV-2 M-pro inhibitors discovered to date. 20, 21, [38] [39] [40] [41] [42] [43] In this review, we focus on the computational methods, especially protein-ligand docking, which have been used to discover new SARS-CoV-2 M-pro inhibitors. We check 61 peer-reviewed manuscripts that use at least one docking step in a virtual screening (VS) protocol to predict SARS-CoV-2 M-pro inhibitors in approved or investigational drugs. We put special emphasis on the validation of the docking process and whether the use of docking scores or other estimates of binding affinity are a reliable way to select new putative inhibitors of SARS-CoV-2 M-pro. For this purpose, we have taken a set of 150 M-pro inhibitors with known experimental bioactivity from the literature and a second set of 81 M-pro known inhibitors and 113 inactive compounds from the COVID Moonshot project to evaluate the reliability of using docking scores as feasible predictors of the potency of a SARS-CoV-2 M-pro inhibitor.

Computational approaches can contribute to drug discovery by reducing the cost and time of drug development and speeding up the analyses of the interactions between a target and candidate drugs. 37 Of all the VS methods, and specifically in drug repurposing, molecular docking is an attractive choice because it can predict the preferred orientation of a drug at the binding site of a target. 44 Molecular docking methods use two independent steps: pose generation and scoring. 45 The first step refers to the methods used to create different ligand poses within the binding site of the protein. The second, scoring, is required to rank the different poses and quantitatively estimate the pose quality. 45 Scoring functions attempt to estimate the binding affinity between the ligand and the protein. 45 We collected 61 articles that use a VS protocol based on protein-ligand docking to predict drugs as SARS-CoV-2 M-pro inhibitors. These articles were published in peer-reviewed journals between the beginning of the COVID-19 pandemic in early February 2020 and November 2020. It should be pointed out that preprints were not included. Table 1 outlines the most relevant information of these 61 articles. Further details and the drugs predicted in each can be found in Supporting Information File 1. As shown in Table 1 , most of these articles used an initial database of approved drugs (e.g., the Drugbank database). A quarter of the articles also included a group of antiviral molecules, such as HIV or Hepatitis C protease inhibitors. The first crystallized structure of the SARS-CoV-2 M-pro protein, the 6LU7 structure released on February 5, 2020 30 and crystallized with the covalent inhibitor N3 was largely used. Before this structure was available, eight articles used a structural model of the M-pro constructed using the homologous protein from SARS-CoV as a template. Subsequently, many other SARS-CoV-2 M-pro structures were released and several articles used the M-pro structure, such as 6W63, complexed with a noncovalent inhibitor. Most of the VS protocols reviewed here used AutoDock Vina or other docking methodologies available at the Schrödinger Drug Discovery suite (i.e., Glide HTVS, Glide SP and Glide XP; see Table 1 ). The majority of these VS protocols used only one docking program, although some of them used two or three. Generally, protocols using multiple docking programs are performed in a stepwise manner; i.e., the programs are used in a funnel approach to reduce the number of hits by using the different prediction algorithms and/or punctuation functions, which is indeed what happens when the increasingly exhaustive methodologies of the Schrödinger package Glide (Glide HTVS, SP, and XP) are used. Nonetheless, there is also room to use different programs in a parallel manner and then evaluate the equivalent poses predicted by each of them, as in our last contribution. 29 Usually, the docking score of the best pose of a reference compound (normally, a known or expected inhibitor) is generally used as a cutoff value for selecting new putative M-pro inhibitors. If the best docking score of a compound is more negative than the docking score of the reference compound, it is usually assumed that the compound will be more active than the reference one. When a reference compound is not used, the most negative docking score values tend to be used as a cutoff to select a group of hit compounds and analyze them in further detail. The predicted interactions between the substrate-binding site of the M-pro protein and each selected compound are usually analyzed. In addition, some reviewed articles use molecular dynamics (MD) to evaluate the binding dynamics of the group of selected hits to the M-pro structure. The molecular mechanics generalized Born surface area (MM-GBSA) or the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) algorithms were generally used to estimate the binding free energies of the putative inhibitors.

The best way to validate the methodology and results of a VS protocol is to experimentally prove the bioactivity of some selected hits. Only two of the 61 articles reviewed confirmed their computational predictions in vitro. 29, 46 When this is not possible, the methodology should be subject to a computational validation. 37 Table 1 and Supporting Information File 1), only two 47,48 converted the extracted ligand to SMILES format and then back to 3D. This is done to lose the binding coordinates of the ligand and evaluate the docking accuracy from scratch, similar to how the compounds are predicted. Because docking calculations are very sensitive to the starting geometries of ligands, 49 it may also be beneficial to re-run the re-docking with different starting conformations each time. 50 In addition to re-docking, it is also recommended to use cross-docking to try to predict the binding pose of a ligand using a different PDB structure. In this way, the possible effect of protein flexibility can be evaluated or the best protein structure identified when several are available. However, re-docking and crossdocking cannot suitably validate an entire VS process or each of its steps. In addition, if docking scores are used to rank the bioactivity of the predicted compounds, it needs to be shown that they correlate with the bioactivity.

Without a proper validation, the predictions obtained are speculative and dubious. A VS protocol can be computationally validated by applying the same VS protocol to a set of active compounds and to a set of inactive or decoy compounds (when a group of inactive compounds is not available). The more accurate the methodology is, the more MACIP ET AL. true positives (i.e., active compounds that pass the VS procedure or VS step) and true negatives (i.e., inactive molecules that do not pass the VS procedure or VS step) there will be. To quantify the performance of the entire methodology or each VS step, several metrics can be used. Of these, the most popular are the area under a ROC curve and the Enrichment Factor (EF), which quantify the extent to which a step of the VS can be enriched with active compounds. Only three of the 61 articles reviewed used a group of known M-pro inhibitors to confirm that their VS procedure was able to enrich the predicted compounds with these inhibitors. 29, 51, 52 In one of the articles 52 12 M-pro inhibitors, 10 weak M-pro inhibitors and 114 DUDE-generated decoys were screened to calculate the EF for each step of the VS and to choose the optimal scoring function for the final hit selection. Although some of the 61 articles used re-docking as a validation step, more than the 67% did not apply a validation step (Table 1 ). This lack of validation of the structure-based approaches to drug repurposing that target M-pro and other SARS-CoV-2 proteins has been described elsewhere. 53, 54 In a survey of the literature before 26 August, Bellera and coworkers 54 reviewed 96 articles that reported the use of molecular docking for identifying potential compounds against SARS-CoV-2 M-pro. None of the 96 articles reported any level of experimental validation and 40.6% of the articles did not perform any kind of in silico validation. 54 We agree with Bellera and coworkers that "the preceding figures are surprising, considering the known fact that the performance of docking studies is highly dependent on the system under study, and the high false-positive rate associated with docking-based VS". 54 An interesting approach used in some of the articles reviewed 48,52,55-57 was to add a pharmacophore-based procedure before the docking step to enrich the database with some characteristics of the reported M-pro inhibitors or M-pro co-crystallized ligands, or to consider only the compounds that can engage in specific interactions with the M-pro active site. This strategy makes it possible to identify which of the initial number of compounds are most likely to be inhibitors, even though it requires prior knowledge of the interactions between the receptor and its ligands. Thus, it cannot be applied in early attempts, when little information is available, but it becomes a more powerful tool as more information arises. Figure 2 shows that the 61 VS protocols analyzed predict very few M-pro inhibitors in common. It could be argued that this lack of agreement about the potential inhibitors is due to differences in the initial set of compounds analyzed and the methods used. However, Figure 3 shows that when different protocols using similar initial datasets are compared, such as FDA-approved drugs ( Figure 3A ) or approved and investigational drugs ( Figure 3B ), very few compounds are predicted by two protocols even if the same PDB structure and docking program have been used ( Figure 3 ). Some of the compounds most commonly predicted as inhibitors of SARS-CoV-2 M-pro in several of the 61 VS protocols reviewed are: the covalent inhibitors of the HIV-protease ritonavir, saquinavir, indinavir, lopinavir and nelfinavir; other antiviral compounds, such as the hepatitis C protease inhibitors simeprevir and paritaprevir; and the HIV integrase inhibitor raltegravir. All of these compounds were predicted by more than five different articles ( Figure 2 ). As these antiviral compounds were initially used in clinical trials to combat the SARS-CoV-2 pandemic, they are also often selected to be included among the final hits of the VS protocols analyzed. Ritonavir inhibits cytochrome P450-3A4, and is often simultaneously used with lopinavir or other HIV or hepatitis C protease inhibitors since it increases their half-life. Although ritonavir was found to inhibit the 

Note: Information is shown about the initial database, the PDB structure, the protein-ligand docking method, whether they use molecular dynamics or not, and the validation method used (if any).

Abbreviations: FDA, Food and Drug Administration. a % Of articles does not necessarily add 100% because some articles may be included in more than one group.

F I G U R E 2 Dendrogram and bar plot of the compounds that are most predicted to be inhibitors of M-pro in several VS. The dendrogram clusters the compounds in terms of their structural pairwise similarity established by the Tanimoto coefficients calculated from the ECFP6 circular fingerprint from each compound. The bar plot represents the number of times that each compound has been predicted as a putative M-pro inhibitor in the reviewed articles (VS occurrences). The in vitro activity, when available, is expressed as pIC 50 values and represented in a green scale. The only compounds displayed are those that are predicted in two or more different VS or for which experimental pIC 50 is available. The names of the compounds with known activity and those with five or more VS occurrences are displayed. VS, virtual screening SARS-CoV-2 M-pro in cell culture, 58 high concentrations are required to achieve significant inhibition, so it will be of limited clinical relevance. 58 The results of several clinical trials that have evaluated the role of lopinavir/ritonavir combination therapy in patients with COVID-19 have shown little or no improvement. [59] [60] [61] Remdesivir was also predicted as an M-pro inhibitor by 7 of the 61 articles. This compound was the first compound approved by the FDA to treat patients with severe symptoms of COVID-19. However, remdesivir is an adenosine nucleoside triphosphate analog that inhibits the SARS-CoV-2 RNA-dependent RNA polymerase and induces an irreversible chain terminator. So, it is surprising that it is predicted to be a SARS-CoV-2 M-pro inhibitor. There is no experimental evidence to suggest that remdesivir binds to SARS-CoV-2 M-pro. 62 In addition, remdesivir is a prodrug, converted to its active form by host enzymes, and this was often not taken into account in the VS protocols analyzed. To the best of our knowledge, only one study has docked remdesivir and its active form to SARS-CoV-2 M-pro and suggested that both molecules have a comparable affinity against SARS-CoV-2 M-pro. 62 More experiments are required to precisely determine if, in addition to inhibiting the RNA-dependent RNA polymerase of SARS-CoV-2, remdesivir's mechanism of action includes the inhibition of M-pro. falls outside the scope of the present work and, for the sake of brevity, no further discussion will be conducted.

In the following sections we describe a group of known SARS-CoV-2 M-pro inhibitors and inactive compounds, and show how their bioactivity can be used to validate a protein-ligand docking step. moderate or low inhibitory activity; compounds, such as carmofur, ebselen, disulfiram, PX-2, shikonin and tideglusib, whose inhibition potencies decreased in the presence of reducing agents, such as DTT, and are considered to be nonspecific inhibitors 73, 74 ; compounds such as shikonin, which quench the signal used to evaluate its activity and therefore may represent a false positive of the analysis 73 ; and compounds such as the HIV-protease inhibitors lopinavir, indinavir, nelfinavir saquinavir, and tipranavir, which have not shown M-pro inhibitory activity in some concentrations analyzed. 58, 64, 75, 76 To test the hypothesis that inhibiting the enzymatic activity of M-pro will inhibit SARS-CoV-2 replication, a cellular antiviral assay is usually performed and an EC 50 Boceprevir, calpain inhibitors I, II, and XII, carmofur, cinanserin, disulfiram, ebselen, GC376, N3, narlaprevir, PX-12, shikonin, telaprevir and tideglusib are some of the covalent inhibitors described for the SARS-CoV-2 M-pro (see Figure S1 and Supporting Information File 2). The role of covalent inhibitors in drug discovery is controversial. Some of the risks they pose are toxicity, immune-mediated drug hypersensitivity, nonspecificity, and hyperreactivity that might lead to further drug-induced toxicity (e.g., hepatotoxicity, mutagenicity, or carcinogenicity). 80 However, three potential benefits are that the high biochemical efficiency may lead to lower doses and reduced off-target effects, lower drug resistance and fewer cases of decreased potency due to competing endogenous substrates. 80 Reversible or irreversible covalent inhibitors that have some kind of specificity for a target or group of targets must first be recognized by the target binding site to place a reactive functional group, usually referred to as a warhead, in an appropriate position to form a covalent bond between the inhibitor and its target. 21, 81 The formation of the covalent bond depends not only on the correct structural complementarity between the protein and the inhibitor, but also on the appropriate chemical reactivity of the inhibitor and the protein environment that stabilizes the covalent complex. 82 The protonation state of catalytic Cys145 and His41 and His172 is crucial for the activity variation caused by pH changes and the M-pro catalytic mechanism [83] [84] [85] and may be crucial to the action of covalent inhibitors. The majority of SARS-CoV-2 covalent inhibitors are large substrate mimetics with an electrophilic warhead that covalently binds with the catalytic Cys145 sulfur atom. 21 But other more nucleophilic cysteines, such as Cys44 located near the substrate binding pocket, are additional sites for covalent linkage. 85 Table 2 shows such covalent warheads, as acrylamide, chloroacetamide, vinylsulfonamide, nitrile, a Michael acceptor group, alphaketoamide, aldehyde, disulfide and several methyl ketone groups, which have been used here to identify putative M-pro covalent inhibitors. Whereas some covalent warheads, such as acrylamide and chloromethyl ketones, form irreversible bonds with their biological targets, others, such as nitriles or electron-deficient ketones, have been found to form a reversible covalent bond. 21, 80 For irreversible covalent inhibitors, if a sufficient period of time is allowed, inhibition is expected to be complete. 86 91 Although MPI3 is ranked second in potency as a SARS-CoV-2 M-pro inhibitor, its inhibition of SARS-CoV-2 replication is much lower than other compounds, which may be explained by the compound's low cell stability. 91 UAWJ248 is a GC376 analog with an alpha-ketoamide reactive warhead that binds irreversibly to Cys145. 94 The IC 50 of UAWJ248 is 0.012 µM, 3.2-fold more potent than GC376. 94 Another set of SARS-CoV-2 M-pro inhibitors and inactive compounds can be obtained from the COVID Moonshot project 95,96 set up to develop M-pro inhibitors. It focused on turning early fragment-screening results into potent compounds. 96 Drug-designers the world over have proposed more than 10,000 M-pro inhibitors, and over 1000 compounds have been either ordered or synthesized and tested for activity against SARS-CoV-2 M-pro using two complementary biochemical assays: a fluorescence based assay and a RapidFire Mass Spectrometry assay. 96 The Fluorescence M-pro inhibition assay consists of a screening in duplicate at 20 and 50 µM. Compounds with a value greater than 50% M-pro inhibition at 50 µM are confirmed by a dose response assay and the value of IC 50 is calculated. 96 For the RapidFire Mass Spectrometry assay, compounds are triaged by testing the % of inhibition at a final concentration of 20 and 50 µM, and IC 50 values are calculated from dose response curves. 96 From the COVID Moonshot activity data available on the August 18, 2020, we selected those compounds that have a pIC 50 difference between the two activity assays of less than two units. In addition, further quality control steps were carried out: (i) a compound was not selected if the percentage of inhibition at 20 µM was higher than the percentage at 50 µM or (ii) if the percentage of inhibition at 50 µM and the IC 50 of a compound were both simultaneously higher than 50. Finally, compounds with undefined chirality were discarded. Figure S2 

Although molecular docking programs can usually generate ligand poses that are similar to the crystallographic conformation for several targets, 98 protein-ligand docking has several limitations. One of these is that, for practical reasons, most docking methods use a rigid protein approximation, where the ligand is treated as flexible, but the protein conformation is restricted. 45, 99 Some methods, such as ensemble docking which takes place in an ensemble of protein conformations, 100 enable protein flexibility to be analysed. Another limitation is that, contrary to what is expected, the poses and docking scores obtained by docking can be heavily dependent on the ligand input structure, 49 so small changes in the ligand input conformation can lead to large differences in the docked poses. 49 One of the major limitations of the scoring functions used by docking programs is that they do not always make a useful prediction of ligand binding affinity. 36, 98 Thus, the best energy score is not a reliable criterion for selecting the best solution in common docking applications. 101 For these reasons, docking scores should not be used as a measure or threshold for compound activity, but rather to enrich the library by discarding those compounds that do not fit inside the binding site. 37 It should also be noted that the docking scores of different docking programs cannot be directly compared because the scores are dependent on the force fields and protocols used for each program. Another limitation of molecular docking is how they deal with water molecules present in the binding site during the docking process 45, 102 which can lead to errors when trying to ascertain the possible interaction between the ligand and the target. Finally, the ability of a docking program to separate decoys from active compounds is usually strongly dependent on the protein structure used and the similarity between the screened ligands and the co-crystallized ones. 36 We 105 For Glide, we used three distinct docking methodologies: Glide HTVS, Glide SP and Glide XP. So in total we considered 5 different docking methods, which appeared to be the most common in the reviewed articles (see Table 1 ). Briefly, the three methodological approaches from the Schrödinger package Glide differ from each one. Essentially, Glide HTVS and Glide SP use the same docking algorithm, but their main difference is that Glide HTVS minimizes the number of intermediate conformations during the docking procedure and the accuracy of the final torsional refinement and sampling. 106 On the other hand, Glide XP uses a more exhaustive and sophisticated scoring function and sampling process, and is stricter in terms of ligand-receptor shape complementarity. 107 We used the 6LU7 structure 30 because it is the most used structure in molecular docking studies of the SARS-CoV-2 M-pro (see Table 1 ). The 6WQF structure of unliganded SARS-CoV-2 M-pro was also used as it was suggested that this structure may provide more relevant information at physiological temperatures, which could be helpful in protein-ligand molecular docking studies. 31 which generated one conformation per compound and discarded unspecified chiralities.

The most negative docking scores obtained for each compound and each protein-ligand methodology were correlated with the inhibitory potency, measured as pIC 50 values. Figure 4 and Figure S4 show that for both datasets, the correlations were far from satisfactory. The correlations improved if covalent and noncovalent inhibitors were treated separately (see Figure 4 and Figure S4 ). For the 6LU7 structure, and considering solely the covalent inhibitors extracted from the literature, correlations were negative, as one would expect because the more negative the docking score, the higher pIC 50 value ( Figure 4A -E). The best correlation had a Pearson's r coefficient of −0.335 (p value 0.003) for the covalent inhibitors when AutoDock Vina was used ( Figure 4E ). However, the Pearson correlation coefficients for the noncovalent inhibitors were positive or around zero ( Figure 4A-E) . For the MACIP ET AL. | 13 set of 81 M-pro inhibitors from the COVID MoonShot project ( Figure 4F-J) , most of the correlations were unexpectedly found to be positive. Conclusions were similar when the 6WQF structure was used ( Figure S4 ). This lack of correlation between the bioactivities and docking scores for this target was previously reported 115, 116 and questions the reliability of using a docking score as a cutoff value for selecting new putative M-pro inhibitors or predicting the relative bioactivity of a compound by comparison with reference compounds or even with other predicted compounds.

To overcome the limitations of docking programs, they can be combined with other methods. Standard molecular dynamics or binding free energy estimations, such as MM-GBSA and MM-PBSA enable the protein flexibility to be explored. MM-GBSA or MM-PBSA are popular methods for estimating ligand-binding affinities with a modest computational effort. 117 Their results are considered to be more accurate than those of most docking scoring functions 118 has proven to be a promising strategy for identifying the correct binding poses and correctly ranking the binding affinities of a series of ligands. 118 However, the success of these methods depends on the target structure 117 and they cannot be used to predict true drug candidates in drug design without experimental verification because their accuracy is relatively limited. 118 To assess how successfully these methods predict the bioactivity ranking of the two sets of known M-pro inhibitors presented above, we used the MM-GBSA minimization available at Prime 119 to re-score the best docking pose obtained with the five docking methods and two SARS-CoV-2 M-pro structures, and to estimate the ΔG value of ligand-binding affinity for each compound. Figure 5 and Figure S5 show the correlation between the pIC 50 and the estimated ΔG values. A negative correlation is expected, because the higher the pIC 50 of a compound is, the lower the ΔG value. Figure 5 and Figure S5 show that most correlations were positive, even though noncovalent and covalent inhibitors were treated separately. Moderate negative correlations were obtained for covalent inhibitors from the bibliography ( Figure 5A -E and Figure S5A -E). The best Pearson r coefficient (with a value of −0.303) was obtained with the covalent inhibitors from the bibliography docked to the 6LU7 structure with the FRED program ( Figure 5A ). Thus, for the inhibitors and M-pro structures assayed here, the MM-GBSA algorithm was not able to correct the lack of correlation obtained with the docking programs. Figure S6F ). For the 6LU7 structure, the best AUC was obtained with the Glide XP docking poses of the noncovalent inhibitors and ΔG values estimated with the MM-GBSA method ( Figure 6I ).

To test if there is a correlation between the pIC 50 of a group of SARS-CoV-2 M-pro inhibitors and their ΔG values without using docking, from the COVID Moonshot activity data we selected a group of 40 noncovalent inhibitors that were co-crystallized with the SARS-CoV-2 M-pro (Supporting Information File 5). The 3-D structures of the protein-ligand complex of these compounds, available from Fragalysis, 120 were used to estimate the proteinligand affinity, expressed as ΔG values, using the K Deep server. 121 In this server, the structure of the protein and the ligand is represented using 8 pharmacophoric-like features (i.e., hydrophobic, aromatic, hydrogen-bond donor and acceptor, positive and negative ionizable, metallic and total excluded volume) and protein-ligand affinity is predicted using a Deep Convolutional Neural Network pre-trained with the PDBbind v.2016 database. 121 Figure 7 shows that the correlation between the pIC 50 and ΔG values is good, with a Pearson correlation coefficient of −0.688 (p value 9.32E-07). However, this correlation decreased when the ligands were transformed to SMILES format to lose the binding coordinates of the ligand and were docked with the five docking programs used above (Figure 8 and shows that for the two SARS-CoV-2 M-pro structures and the five docking methods used here, these methodologies were not able to predict the crystallographic pose as the best docking pose, as it has recently been shown. 122 Again this reinforces the idea that it is essential that docking results be validated before use.

Although the SARS-CoV-2 pandemic needed an accelerated process of drug development, measures are required to safeguard this process. Dotolo and coworkers put this idea into words with the proverb "haste makes waste", and

remarked that "what is true for popular wisdom is doubly true for scientific research". 53 Overconfident statements and conclusions that are not fully supported by experimental evidence are frequently found in articles that use protein-ligand docking to find SARS-CoV-2 M-pro inhibitors. 54 The methods used and the results obtained by computational approaches must be validated so that these methods are not devalued and efforts focus on the most promising compounds. If docking scores are used to rank or select a set of compounds or to compare the potency of two inhibitor compounds, it must first be shown that there is a correlation between docking scores and activity or potency, for example expressed as the IC 50 . If there is no such correlation, there is no reason to apply this F I G U R E 8 Correlation between the pIC 50 methodology. A VS protocol can be computationally validated by applying the same VS protocol to a set of both active and inactive compounds. Therefore, the methodology is expected to be able to selectively identify the known active compounds from the validation set. The use of inactive compounds for this validation is crucial because they act as a negative control. Of course, the validation of a VS protocol with active and inactive compounds requires prior knowledge of the target, so it is not applicable if information is scarce, as is the case when targets are new or poorly understood. However, it must be used as an efficient validation tool when more information is available. The set of SARS-CoV-2 M-pro inhibitors and inactive compounds reviewed here could be helpful in validating future screenings.

The flexibility and plasticity of the SARS-CoV-2 M-pro make it a challenging target for small-molecule inhibitor design. 71 Thus, techniques that have been applied to other targets are not always effective. When using any methodology, such as protein-ligand docking, it is important to consider not only its well-known advantages, but also its weaknesses. Binding free energies solely based on docking poses are, in general, insufficiently reliable. 116 Here, in two large groups of SARS-CoV-2 M-pro inhibitors, using two different SARS-CoV-2 M-pro structures and five protein-ligand docking methods we have shown that there is not a good correlation between the bioactivity and such affinity scores, as the docking scores or the ΔG calculated with the MM-GBSA method. In addition, these affinity scores cannot distinguish between compounds with or without M-pro inhibitory activity, especially if covalent and noncovalent inhibitors are analyzed together. This is not to suggest that protein-ligand docking is useless. On the contrary, it is indeed an invaluable tool for reducing the initial compounds in a virtual screening when used in the initials steps, for plausible pose prediction and for semiquantitative assessment of the inhibitory power of a ligand. 116 46, 124, 136 Advances in computer power, enhanced sampling algorithms, and increase of force field accuracy has led to newer FEP implementations that has enabled accurate and reliable calculations of protein-ligand binding free energies. 137 Only when combined with other methods, should the results of automated protein-ligand docking be considered worthy for further experimental testing.

We thank OpenEye Scientific Software and Cresset for kindly providing us with a software bursary to use their programs. This manuscript has been edited by the English language service of our university. This project has Research Group at URV for two years as a trainee student, where she has worked on protein-ligand molecular docking, lead optimization and drug development as well as data analysis.

Bryan P. Saldivar-Espinoza has a bachelor degree in telecommunications engineering and he is a PhD student at the Cheminformatics & Nutrition Research Group of the URV. He has worked applying Machine learning on medical images for tuberculosis and anemia diagnosis. Similarly, he has applied machine learning methods to text mining in a public policy context and process optimization in a business operation framework. or anti-diabetic (i.e., DPP-IV inhibitors and PPAR-gamma partial agonists) compounds and tools for target

An interactive web-based dashboard to track COVID-19 in real time

Worldometers Coronavirus Update (Live)

The socio-economic implications of the coronavirus pandemic (COVID-19): a review

University Vita-Salute San Raffaele COVID-19 literature monitoring working group. The first 10 000 COVID-19 papers in perspective: are we publishing what we should be publishing?

Pandemic publishing poses a new COVID-19 challenge

What is the role of cheminformatics in a pandemic?

Waste in covid-19 research

The molecular biology of coronaviruses

One year update on the COVID-19 pandemic: where are we now?

A novel coronavirus associated with severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A new coronavirus associated with human respiratory disease in China

The architecture of SARS-CoV-2 transcriptome

Emerging coronaviruses: genome structure, replication, and pathogenesis

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Protease targeted COVID-19 drug discovery: what we have learned from the past SARS-CoV inhibitors?

Papain-like proteases as coronaviral drug targets: current inhibitors, opportunities, and limitations

Potential SARS-CoV-2 main protease inhibitors

What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinicalgrade soluble human ACE2

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

Treatment for COVID-19: an overview

A Review of SARS-CoV-2 and the ongoing clinical trials

Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography

Molecular field extrema as descriptors of biological activity: definition and validation

Electrostatic complementarity as a fast and effective tool to optimize binding and selectivity of protein-ligand complexes

Drug repurposing: progress, challenges and recommendations

Molecular docking: shifting paradigms in drug discovery

The light and dark sides of virtual screening: what is there to know?

Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19

The recent outbreaks of human coronaviruses: a medicinal chemistry perspective

COVID-19 drug repurposing: a review of computational screening methods, clinical trials, and protein interaction assays

Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities

Drug repurposing approach to combating coronavirus: potential drugs and drug targets

Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases

Computational methods for biomolecular docking

Binding affinity via docking: fact and fiction

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs

Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors

Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach

Effect of input differences on the results of docking calculations

Docking: successes and Challenges

Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: virtual screening and structure based drug design

A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease

A review on drug repurposing applicable to COVID-19

Can drug repurposing strategies be the solution to the COVID-19 crisis?

Drug repurposing against SARS-CoV-2 using Epharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target

Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads

Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with Mpro

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease

Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data

Bepridil is potent against SARS-CoV-2 in vitro

Discovery of M protease inhibitors encoded by SARS-CoV-2

GRL-0920, an Indole Chloropyridinyl Ester

Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach

In silico Drug Repurposing for COVID-19: targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Discovery of Ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19

SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model

Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design

Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2

Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry

Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors

Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection

Uncovering flexible active site conformations of SARS-CoV-2 3CL proteases through protease pharmacophore clusters and COVID-19 drug repurposing

Infectious diseases society of america guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Development of a cell-based luciferase complementation assay for identification of SARS-CoV-2 3CLpro inhibitors

Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies

Expanding the armory: predicting and tuning covalent warhead reactivity

Exploring the mechanism of covalent inhibition: simulating the binding free energy of αketoamide inhibitors of the main protease of SARS-CoV-2

Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL Mpro: insights into enzyme mechanism and drug design

Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography

Proton-coupled conformational activation of SARS coronavirus main proteases and opportunity for designing small-molecule broad-spectrum targeted covalent inhibitors

The resurgence of covalent drugs

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug

A quick route to multiple highly potent SARS-CoV-2 main protease inhibitors

Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative highthroughput screening

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M pro and cathepsin L

COVID moonshot: open science discovery of SARS-CoV-2 main protease inhibitors by combining crowdsourcing, high-throughput experiments, computational simulations, and machine learning

Action of dipeptidyl peptidase-4 inhibitors on SARS-CoV-2 main protease

A critical assessment of docking programs and scoring functions

Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy

Ensemble docking in drug discovery

Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? Molecules

Molecular docking in modern drug discovery: principles and recent applications

Schrödinger Release 2020-3. Glide, Schrödinger

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes

Schrödinger Release 2020-3. Protein Preparation Wizard, Schrödinger

Schrödinger Release 2020-3. Epik, Schrödinger

PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions

AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility

OMEGA 3.1.1.2: OpenEye Scientific Software

Schrödinger Release 2020-3. LigPrep, Schrödinger

QUACPAC 2.0.2.2: OpenEye Scientific Software

QSAR modeling of SARS-CoV M pro inhibitors identifies sufugolix, cenicriviroc, proglumetacin, and other drugs as candidates for repurposing against SARS-CoV-2

Virtual double-system single-box: a nonequilibrium alchemical technique for absolute binding free energy calculations: application to ligands of the SARS-CoV-2 main protease

The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities

End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design

Schrödinger Release 2020-3. Prime, Schrödinger

KDEEP: protein-ligand absolute binding affinity prediction via 3D-convolutional neural networks

Benchmarking the ability of common docking programs to correctly reproduce and score binding modes in SARS-CoV-2 protease Mpro

Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2

Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations

Structure-based virtual screening and biochemical validation to discover a potential inhibitor of the SARS-CoV-2 main protease

Comparative evaluation of covalent docking tools

Theory and applications of covalent docking in drug discovery: merits and pitfalls

Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening

Potential SARS-CoV-2 protease Mpro inhibitors: Repurposing FDAapproved drugs

A computational approach to identify potential novel inhibitors against the coronavirus SARS-CoV-2

Mechanism of inhibition of SARS-CoV-2 Mpro by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity

Multiscale simulations of SARS-CoV-2 3CL protease inhibition with aldehyde derivatives. Role of protein and inhibitor conformational changes in the reaction mechanism

Interactive molecular dynamics in virtual reality is an effective tool for flexible substrate and inhibitor docking to the SARS-CoV-2 main protease

Ensemble docking coupled to linear interaction energy calculations for identification of coronavirus main protease (3CLpro) Non-Covalent Small-Molecule Inhibitors

Benchmark of popular free energy approaches revealing the inhibitors binding to SARS-CoV−2 Mpro

Protein-ligand binding free energy calculations with FEP

Macip Sancho is a PhD student at the Cheminformatics & Nutrition Research Group of the URV currently focused in finding inhibitors of SARS-CoV-2 main protease (Mpro)

As a student trainee in the Department of Biophysics at the UAB he has worked in the analysis of Mycoplasma genitalium membrane proteome in order to find therapeutic targets against its infection

Pol Garcia-Segura is an undergraduate student of a double BSc

Cheminformatics & Nutrition Research Group at URV for a couple of years, performing protein-ligand docking simulations, genomic sequences analysis and data analysis

She has been part of the Cheminformatics & Nutrition fishing. In summer 2016, he was a visitor at the Bender Group at the Department of Chemistry

Gerard Pujadas is graduate in Chemistry by the Universitat de Barcelona (1992) and PhD in Chemistry by the

After this post-doctoral stay, he returned to the URV where in September 2002 he won a permanent position at the Biochemistry and Biotechnology Department. Since then, his main contributions to science has been the development of: (1) several virtual screening workflows for predicting molecules that act as antiinflammatories

Cheminformatics & Nutrition" at the URV that aims to: (1) develop potent antidiabetic compounds from lead molecules identified with our virtual screening workflows; and (2) develop new tools and databases for improving virtual screening workflows performance

Haste makes waste: a critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition